长药控股（300391）投资者索赔案批量获得法院立案，前期已有胜诉

Core Viewpoint - Long Pharmaceutical Holdings (300391) is facing significant legal and financial challenges due to false financial reporting and potential forced delisting from the Shenzhen Stock Exchange, which has led to investor claims for compensation [2][4]. Group 1: Legal Issues - The Wuhan Intermediate People's Court has accepted batch claims from investors against Long Pharmaceutical Holdings, with ongoing efforts to accept more claims [1][3]. - There have been precedents of successful claims by investors against Long Pharmaceutical Holdings, indicating a potential for further compensation opportunities [1][3]. Group 2: Financial Misreporting - The company has been found to have inflated its revenue and profit figures in its annual reports for 2021, 2022, and 2023, with inflated revenues of 215.32 million, 283.74 million, and 233.63 million respectively, representing 9.12%, 17.57%, and 19.51% of reported revenues [2][4]. - The inflated profit totals were 56.40 million, 63.38 million, and 43.71 million for the same years, accounting for 35.62%, 88.23%, and 6.42% of reported profits [2][4]. - The company may face forced delisting due to continuous false reporting of financial metrics over three years, as per the Shenzhen Stock Exchange regulations [2][4]. Group 3: Financial Health - As of the latest report, Long Pharmaceutical Holdings has a significant fund occupation amounting to 179.66 million, which is 92.08% of its latest audited net assets [3][5]. - The company plans to resolve the fund occupation through the transfer of debts with related parties [3][5].